Veldoreotide acetate | GH Secretion Reducer | SOMATOPRIM ACETATE

MedKoo Cat#: 125108 | Name: Veldoreotide acetate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Veldoreotide, also known as Somatoprim, is a unique somatostatin receptor subtypes 2-, 4- and 5-selective analogue which effectively reduces GH secretion in human GH-secreting pituitary adenomas, even in Octreotide non-responsive tumours.

Chemical Structure

Veldoreotide acetate

CAS#Veldoreotide acetate

Theoretical Analysis

MedKoo Cat#: 125108

Name: Veldoreotide acetate

CAS#: Veldoreotide acetate

Chemical Formula: C62H78N12O12

Exact Mass: 1182.5900

Molecular Weight: 1183.38

Elemental Analysis: C, 62.93; H, 6.64; N, 14.20; O, 16.22

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

252845-37-7 Veldoreotide acetate

Synonym

SOMATOPRIM ACETATE; VELDOREOTIDE ACETATE; COR-005 ACETATE; 9F2286627L

IUPAC/Chemical Name

2-((3S,6S,9S,12R,15S,18S)-12,15-bis((1H-indol-3-yl)methyl)-9-(4-aminobutyl)-3,18-dibenzyl-6-((R)-1-hydroxyethyl)-2,5,8,11,14,17,20,25-octaoxo-1,4,7,10,13,16,19,24-octaazacyclooctacosan-1-yl)acetamide acetate

InChi Key

OAISCAWXQQWLIC-NTYYTJCMSA-N

InChi Code

InChI=1S/C60H74N12O10.C2H4O2/c1-37(73)54-59(81)70-50(31-39-18-6-3-7-19-39)60(82)72(36-51(62)74)29-15-26-52(75)63-28-14-25-53(76)66-47(30-38-16-4-2-5-17-38)56(78)68-49(33-41-35-65-45-23-11-9-21-43(41)45)58(80)69-48(32-40-34-64-44-22-10-8-20-42(40)44)57(79)67-46(55(77)71-54)24-12-13-27-61;1-2(3)4/h2-11,16-23,34-35,37,46-50,54,64-65,73H,12-15,24-33,36,61H2,1H3,(H2,62,74)(H,63,75)(H,66,76)(H,67,79)(H,68,78)(H,69,80)(H,70,81)(H,71,77);1H3,(H,3,4)/t37-,46+,47+,48-,49+,50+,54+;/m1./s1

SMILES Code

CC(O)=O.O=C(N)CN1C([C@H](CC2=CC=CC=C2)NC([C@H]([C@H](O)C)NC([C@H](CCCCN)NC([C@@H](CC3=CNC4=C3C=CC=C4)NC([C@H](CC5=CNC6=C5C=CC=C6)NC([C@H](CC7=CC=CC=C7)NC(CCCNC(CCC1)=O)=O)=O)=O)=O)=O)=O)=O

Appearance

To be determined

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 1,183.38 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Paragliola RM, Salvatori R. Novel Somatostatin Receptor Ligands Therapies for Acromegaly. Front Endocrinol (Lausanne). 2018 Mar 7;9:78. doi: 10.3389/fendo.2018.00078. eCollection 2018. Review. PubMed PMID: 29563895; PubMed Central PMCID: PMC5845985. 2: Hána V. [Current and future therapy of acromegaly]. Vnitr Lek. Fall 2016;62(9 Suppl 3):68-72. Czech. PubMed PMID: 27734694. 3: Günther T, Culler M, Schulz S. Research Resource: Real-Time Analysis of Somatostatin and Dopamine Receptor Signaling in Pituitary Cells Using a Fluorescence-Based Membrane Potential Assay. Mol Endocrinol. 2016 Apr;30(4):479-90. doi: 10.1210/me.2015-1241. Epub 2016 Mar 11. PubMed PMID: 26967369; PubMed Central PMCID: PMC5414644. 4: Melmed S. New therapeutic agents for acromegaly. Nat Rev Endocrinol. 2016 Feb;12(2):90-8. doi: 10.1038/nrendo.2015.196. Epub 2015 Nov 27. Review. PubMed PMID: 26610414. 5: Cuevas-Ramos D, Fleseriu M. Somatostatin receptor ligands and resistance to treatment in pituitary adenomas. J Mol Endocrinol. 2014 Jun;52(3):R223-40. doi: 10.1530/JME-14-0011. Epub 2014 Mar 19. Review. PubMed PMID: 24647046. 6: Störmann S, Schopohl J. Emerging drugs for acromegaly. Expert Opin Emerg Drugs. 2014 Mar;19(1):79-97. doi: 10.1517/14728214.2014.875529. Epub 2013 Dec 28. Review. PubMed PMID: 24400774. 7: Veenstra MJ, de Herder WW, Feelders RA, Hofland LJ. Targeting the somatostatin receptor in pituitary and neuroendocrine tumors. Expert Opin Ther Targets. 2013 Nov;17(11):1329-43. doi: 10.1517/14728222.2013.830711. Epub 2013 Aug 31. Review. PubMed PMID: 23991721. 8: Theodoropoulou M, Stalla GK. Somatostatin receptors: from signaling to clinical practice. Front Neuroendocrinol. 2013 Aug;34(3):228-52. doi: 10.1016/j.yfrne.2013.07.005. Epub 2013 Jul 18. Review. PubMed PMID: 23872332. 9: Kliewer A, Mann A, Petrich A, Pöll F, Schulz S. A transplantable phosphorylation probe for direct assessment of G protein-coupled receptor activation. PLoS One. 2012;7(6):e39458. doi: 10.1371/journal.pone.0039458. Epub 2012 Jun 26. PubMed PMID: 22745760; PubMed Central PMCID: PMC3383726. 10: Koch L. Pharmacotherapy: Somatoprim versus octreotide in acromegaly. Nat Rev Endocrinol. 2011 Nov 29;8(2):66. doi: 10.1038/nrendo.2011.211. PubMed PMID: 22124440. 11: Plöckinger U, Hoffmann U, Geese M, Lupp A, Buchfelder M, Flitsch J, Vajkoczy P, Jakob W, Saeger W, Schulz S, Dohrmann C. DG3173 (somatoprim), a unique somatostatin receptor subtypes 2-, 4- and 5-selective analogue, effectively reduces GH secretion in human GH-secreting pituitary adenomas even in Octreotide non-responsive tumours. Eur J Endocrinol. 2012 Feb;166(2):223-34. doi: 10.1530/EJE-11-0737. Epub 2011 Nov 7. PubMed PMID: 22065857. 12: Flyvbjerg A. The role of growth hormone in the pathogenesis of diabetic kidney disease. Pediatr Endocrinol Rev. 2004 Aug;1 Suppl 3:525-9. Review. PubMed PMID: 16444187. 13: Shimon I, Rubinek T, Hadani M, Alhadef N. PTR-3173 (somatoprim), a novel somatostatin analog with affinity for somatostatin receptors 2, 4 and 5 is a potent inhibitor of human GH secretion. J Endocrinol Invest. 2004 Sep;27(8):721-7. PubMed PMID: 15636423. 14: Segev Y, Eshet R, Rivkis I, Hayat C, Kachko L, Phillip M, Landau D. Comparison between somatostatin analogues and ACE inhibitor in the NOD mouse model of diabetic kidney disease. Nephrol Dial Transplant. 2004 Dec;19(12):3021-8. Epub 2004 Oct 19. PubMed PMID: 15494355. 15: Rubello D, Rufini V, De Carlo E, Martini C, Calcagni ML, Sicolo N, Troncone L, Casara D. [New perspectives in diagnosis and therapy of endocrine gastroenteropancreatic (GEP) tumors with somatostatin analogues]. Minerva Endocrinol. 2003 Dec;28(4):259-96. Review. Italian. PubMed PMID: 14752399. 16: Gazal S, Gelerman G, Ziv O, Karpov O, Litman P, Bracha M, Afargan M, Gilon C. Human somatostatin receptor specificity of backbone-cyclic analogues containing novel sulfur building units. J Med Chem. 2002 Apr 11;45(8):1665-71. PubMed PMID: 11931620. 17: Landau D, Segev Y, Afargan M, Silbergeld A, Katchko L, Podshyvalov A, Phillip M. A novel somatostatin analogue prevents early renal complications in the nonobese diabetic mouse. Kidney Int. 2001 Aug;60(2):505-12. PubMed PMID: 11473633. 18: Afargan M, Janson ET, Gelerman G, Rosenfeld R, Ziv O, Karpov O, Wolf A, Bracha M, Shohat D, Liapakis G, Gilon C, Hoffman A, Stephensky D, Oberg K. Novel long-acting somatostatin analog with endocrine selectivity: potent suppression of growth hormone but not of insulin. Endocrinology. 2001 Jan;142(1):477-86. PubMed PMID: 11145612.